Palak Shah, M.D. + Inova Schar Heart and Vascular will receive a $1.4M grant to develop a blood test to optimize care for pediatric heart transplant patients. This research could help kids w/ new hearts live longer lives.

👏 Inova, Christopher O'Connor, Palak Shah #BoldHearts spr.ly/6018b5Ebj

Result of Inova Schar Heart and Vascular study of DOAC in patients with advanced HF with LVAD -- presented at Cardiovascular Research Foundation #THT by Palak Shah and discussed in TCTMD

tctmd.com/news/small-stu…

⁦Palak Shah⁩ shares #LBCT results #DOAC #LVAD pilot study #THT2024 Time now 4 pivotal RCT on anticoagulation in durable #MCS ? ⁦Christopher O'Connor⁩ ⁦Mitchell Psotka⁩ ⁦Iyad Isseh إياد نبيل العسّة⁩ ⁦Mary Looby⁩ ⁦Inova Schar Heart and Vascular⁩ ⁦Inova⁩ ⁦InovaCVfellows⁩

Inova & George Mason University are seeking a post-doctoral research fellow in Advanced Heart Failure. Great opportunity for those looking to accelerate their academic careers.

Vanessa Blumer, MD, FACC Shashank Sinha, MD, MSc, FACC, FAHA Jason F. Goldberg MD MS Mitchell Psotka Inova Schar Heart and Vascular The ISHLT Iyad Isseh إياد نبيل العسّة Abdulla A. Damluji, MD, PhD

Fantastic Inova @IHVInews show at #AHA2023 Palak Shah Garima Sharma M.D Christopher O'Connor Christopher DeFilipp Vanessa Blumer, MD, FACC

Withdrawal of aspirin is safe in #LVAD patients, how about apixaban instead of warfarin?

Introducing the DOAC LVAD Study—design paper online NOW Journal of Cardiac Failure 👇
#ARIES #DOAC #LVAD

Palak Shah Mary Looby
Christopher O'Connor @IHVInews

doi.org/10.1016/j.card…

#Tweetorial (1 of 6) dd-cfDNA has significant evidence in diagnosing ACR and AMR. GEP can diagnose ACR only, and HLA antibodies are associated with AMR. More data needed for MicroRNA and Proteomics and in CAV. Palak Shah Lauren K. Truby Annette Jackson Kiran Khush Dr. Agbor-Enoh Omics Lab

In depth review within Circulation that provides comprehensive guidance for clinicians and scientists on assessment of #DSA , #cellfreeDNA and highlights disparities in care amongst Black #hearttransplant patients. Dr. Agbor-Enoh Omics Lab Jason F. Goldberg MD MS Josef Stehlik Shelley Hall

Newly published guidelines on care of the #hearttransplant patient from the The ISHLT in @JHLT:

jhltonline.org/article/S1053-…

Congrats to the chairs of the The ISHLT #MCS core academy on a wonderful program and packed audience. Dynamic session with excellent participant engagement. Even the teachers learned! Now off to #AHA2022 . Stavros George Drakos Jennifer Cowger Manreet Kanwar Farooq Sheikh Rebecca Cogswell

The ⁦⁦@IHVInews⁩ HF/MCSTXP team celebrating our OneTeam ⁦HFSA⁩ 2022. ⁦Mitchell Psotka⁩ ⁦Carolyn Rosner⁩ ⁦Shashank Sinha, MD, MSc, FACC, FAHA⁩ ⁦Behnam N. Tehrani, MD⁩ ⁦Lauren Cooper⁩ ⁦Iyad Isseh إياد نبيل العسّة⁩

Super fun debates in #cardiogenicshock ongoing HFSA. Shock team v. No teams, RCTs v. No RCTs. Jennifer Cowger Manreet Kanwar Vanessa Blumer, MD, FACC David Baran Rachna Kataria, MD Lauren Cooper Jason N. Katz

Clinical and translational reviews in myocardial recovery with #MCS for physicians and scientists. A step by step guide to help realize recovery in your #LVAD / #HF patients. Jennifer Cowger Rebecca Cogswell Jane Wilcox, MD, MSc The ISHLT Jeff Teuteberg Anju Bhardwaj MD FACC Ravi Karra Finn Gustafsson

Time to consider a trial of temporary RVADs in #HF patients high-risk for RVF going for #LVAD implant. Is this the right tool or should we be thinking about AI of RV function on ECHO or dare I say RVF risk score? Jeff Teuteberg Manreet Kanwar Rebecca Cogswell Susan Joseph MD

Excellent #MCS conference before AHA for #HF and transplant faculty, fellows and allied healthcare providers interested in an one-day comprehensive course on #LVAD , #CS and #TCS . Register 👇

From GRAfT, ⬆️levels of #hearttransplant injury / #cfDNA early after TXP in Blacks is associated with a ⬆️risk of AMR. Need to better understand the mechanisms of injury and reduce early injury after TXP to improve patient outcomes. Excellent editorial:
jhltonline.org/article/S1053-…

Welcoming our new Director of TXP ID Sajal Tanna, MD, MPH to @IHVInews. Great to catchup #ATCBoston2022 . Look forward to partnering as we to continue to innovate and disrupt in #hearttransplant . Shashank Sinha, MD, MSc, FACC, FAHA Mitchell Psotka Christopher O'Connor Shashank Desai Iyad Isseh إياد نبيل العسّة Inova Jamie Kennedy

Totally agree with Alexandre Loupy that cfDNA is not the end all be all in #hearttransplant . RCTs are needed to prove clinical utility and eliminate surveillance EMB in ~80% low-risk pts. For the other 20% of pts a multi-marker approach is needed. Shelley Hall Mandeep R. Mehra, MBBS, MSc, FRCP (London)

Our clinical guide to help you reverse remodel and achieve myocardial remission/recovery in HF pts w/wo an #LVAD . Even if you don’t explant the device, clinical outcomes will improve which is key to advance our field and enhance patient QOL / survival. Ravi Karra Aditya Mandawat, MD